Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback